Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02262026 · ClinicalTrials.gov registry record · Phase 1
The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT02262026 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 49 participants.
The verdict
NCT02262026, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
Functional neuroimaging of alcoholism vulnerability: glutamate, reward, impulsivity, and Pavlovian-to-instrumental transfer (PIT), part II Saracatinib
Interventions
- DRUG Placebo
- DRUG 125 mg AZD0530
- DRUG 50 mg AZD0530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2014-11-01 |
| Est. Completion | 2019-04-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02262026
The ClinicalTrials.gov registry entry for NCT02262026 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02262026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02262026 about?
NCT02262026 is a clinical study titled "The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism". Functional neuroimaging of alcoholism vulnerability: glutamate, reward, impulsivity, and Pavlovian-to-instrumental transfer (PIT), part II Saracatinib
What is the current status of trial NCT02262026?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2014-11-01. Estimated completion is 2019-04-26.
What interventions are being tested in trial NCT02262026?
The interventions under investigation include: Placebo (DRUG), 125 mg AZD0530 (DRUG), 50 mg AZD0530 (DRUG).
Who is sponsoring clinical trial NCT02262026?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.